# Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma

> **NCT00744640** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 46 (actual)

## Conditions studied

- Locally Advanced Pancreatic Cancer
- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** gemcitabine, oxaliplatin, capecitabine

## Key facts

- **NCT ID:** NCT00744640
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2009-02
- **Final completion:** 2009-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2010-01-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00744640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00744640, "Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00744640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*